45) experienced the largest benefits—3.29%, 3.12%, and 3.64% increases at 50:1, 25:1, and 12.5:1, respectively—demonstrating a clear trend toward greater LM1019 efficacy in those with lower LDL levels.
← all excerpts
<i>Lacticaseibacillus rhamnosus</i> LM1019 Enhances Natural Killer Cell Activity in Defined Adult Subsets: A Double-Blind, Placebo-Controlled Trial.
1
—
—